Production of Egg Yolk Antibodies Specific to House Dust Mite Proteins

Abstract

PurposeHouse dust mites (HDMs) are an important source of indoor allergens associated with asthma, rhinitis and atopic dermatitis. Chicken immunoglobulin (Ig) Y is known to be a good alternative to mice and rabbit antibody production. In this study, we produced IgYs specific to HDMs and investigated their IgE immunoreactivities.Materials and MethodsTotal IgYs were isolated from the yolks of White Leghorn hens immunized with either Dermatophagoides pteronyssinus or D. farinae protein extract. Control antibodies were separated from the yolks of immunized hens with phosphate buffered saline. IgYs specific to HDMs were analyzed using enzyme-linked immunosorbent assay and Western blotting analysis.ResultsThe concentration of egg IgY specific to D. farinae in an immunized hen increased and the highest achieved was 661.3 ug/mg (per an egg) on day 47, compared with 760 ug/mg IgY specific to D. pteronyssinus on day 16. The D. pteronyssinus or D. farinae-specific IgY was detected by binding of each mite proteins, and their immunoreactivities were elevated dependent of the specific IgY concentration.ConclusionIgY specific to HDMs may be a promising antibody for immunological diagnosis as well as identification of possible resistance relating to HDM allergy.

IgY antibodies for the immunoprophylaxis and therapy of respiratory infections

“…46 It has also been used against candidiasis, dental caries, and periodontitis of the oral cavity [47][48][49] ; gastritis and Helicobacter pylori 50,51 ; intestinal disorders such as celiac disease, cholera, and diarrhea [52][53][54] ; metabolic syndrome 55 ; and illness caused by environmental factors, such as norovirus, dust mites, and snake venom. [56][57][58] Our group previously developed a reliable murine model for H. pylori infection. 59 In addition, we developed IgY antibodies in chickens that target a pathogenic H. pylori strain and used these antibodies to treat infected mice.…”

Chicken Egg Yolk Antibodies (IgY) for Prophylaxis and Treatment of Rotavirus Diarrhea in Human and Animal Neonates: A Concise Review

“…Starting in the early 1990s, some investigators in our group introduced the anti-rotavirus IgY for oral passive immunization among young children and animals as a specific treatment modality for rotavirus diarrhea with a potential for both prophylactic and therapeutic applications. Since then, the efficacy of IgY has been demonstrated in the treatment and prevention of infectious diseases of the skin (Acne) ( Selven et al , 2012 ), oral cavity (candidiasis, dental caries, periodontitis,) ( Ibrahim et al , 2008 ; Nguyen et al , 2011 ; Yokoyama et al , 2007 ), stomach (gastritis) ( Suzuki et al , 2004 ) intestine (celiac disease, cholera, diarrhea) ( Gujrat et al , 2012 ; Hirai et al , 2010 ; Rahman et al , 2012 ), metabolic syndrome ( Hirose et al , 2013 ), cystic fibrosis ( Nilsson et al , 2008 ) and others (environmental care e.g., Norovirus, Influenza, House dust mite etc., snake venom,) ( Dai et al , 2012 ; Lee et al , 2014 ; Lee et al , 2015 ; Nguyen et al , 2010 ). The aim of this review is to summarize the highlights of cumulated information on anti-rotavirus IgY with focus on in vitro investigations, clinical trials in human and animal subjects as well as the potential direction and future needs in antirotavirus IgY clinical research.…”